Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead’s 4th Annual Pain Therapeutics Summit

Share Article

Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics.

The Agenda for Arrowhead’s 4th Annual Pain Therapeutics Summit, set to take place on October 4th-5th, 2010 in Philadelphia, has been announced.

Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics, regulatory issues, commercialization of new pain therapies and various other topics integral to the field of pain therapeutics.

Topics covered at this year’s Summit include:

Regulatory hurdles in pain drug development
Animal models for pain drug discovery research
Clinical development models
Trial Designs
Abuse-deterrent opioids
Long-term opioid use
Next generation therapeutics for pain
Trends in pain drug development
Preclinical and clinical activity in pain space
FDA Update
Market direction of the field of pain therapeutics
Translational pain research
Competitive landscape
Mixing basic science, drug development and clinical practice
Discovery targets: TRPV, TRPA, TRPM8, NGF antagonists, Nav1.7, P2X4, P2X7
Abuse liability and safety (REMS)
Novel mechanisms of action for future pain therapies

Speakers at this year’s event include:

Jeffrey S. Mogil, Ph.D., E.P. Taylor Chair in Pain Studies, Canada Research Chair in Genetics of Pain, McGill University

William K. Schmidt, Ph.D., Vice President, CG Pharmaceuticals

Theodore Cicero, Ph.D., Professor of Psychiatry, Anatomy & Neurobiology, Washington University in St. Louis
David Hewitt, MD, Senior Director, Clinical Neuroscience, Merck & Co.

Gary W. Jay, MD, DAAPM, FAAPM, Senior Director, Clinical Disease Area Expert - Pain, Pfizer, Inc.

Lynn R. Webster, MD, FACPM, FASAM, Medical Director and Founder, Lifetree Clinical Research & Pain Clinic, Director-At-Large, American Academy of Pain Medicine

Dr. Luca Benatti, CEO, Newron

Andy Billinton, Ph.D., Behavioral and Translational Pharmacology Leader, Pain, Neurosciences, GlaxoSmithKline

Jennifer Bolen, JD, Founder, The Legal Side of Pain (A division of the J. Bolen Group, LLC)

Michael Gold, Ph.D., Associate Professor, Anesthesiology, University of Pittsburgh

James R. Gorman, MD, Ph.D., CEO and Chief Medical Officer, BioAssets Development Corporation

Hyungsuk Kim, DDS, Ph.D, Staff Scientist, NINR, National Institutes of Health

Jennifer Laird, Ph.D., Senior Principal Scientist, AstraZeneca R&D

Frédérique Menzaghi, Ph.D., Vice President Research & Development, Cara Therapeutics

Patricia Richards, MD, Ph.D., Chief Medical Officer, QRx Pharma

For the complete list of speakers as well as the agenda, please visit http://www.paintherapeuticsummit.com or call 1-312-244-3703.

###

Share article on social media or email:

View article via:

Pdf Print